20 Sep

A Look at Shire’s Valuation on September 19

WRITTEN BY Mike Benson

Shire’s valuation

Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.

Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise from $3.7 billion in the second quarter of 2017.

A Look at Shire’s Valuation on September 19

The chart above shows a comparison of Shire’s revenues and EPS since the first quarter of 2017. Now let’s take a look at the company’s valuation multiples.

Forward PE

Shire is currently trading at a forward PE multiple of ~11.4x, while the industry average forward PE multiple is ~15.5x as of September 19. Competitors Sanofi (SNY), GlaxoSmithKline (GSK), and AstraZeneca (AZN) are trading at forward PE multiples of 13.3x, 13.2x, and 21.5x, respectively.

Forward EV-to-EBITDA

Shire is currently trading at a forward EV-to-EBITDA (enterprise value-to-EBITDA) multiple of ~10.6x, higher than the industry average of ~11.8x as of September 19. Sanofi, GlaxoSmithKline, and AstraZeneca are trading at forward EV-to-EBITDA multiples of 10.8x, 9.7x, and 14.0x, respectively.

Forward EV-to-revenue

Shire is currently trading at a forward EV-to-revenue multiple of ~4.6x, while the industry average is ~4.7x as of September 19. Sanofi, GlaxoSmithKline, and AstraZeneca are trading at forward EV-to-revenue multiples of 3.2x, 3.1x, and 4.7x, respectively.

The Invesco International Dividend Achievers ETF (PID) holds 0.3% of its total investments in Shire and 2.6% in Sanofi.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.

172.31.16.229